Ophthalmics Collaboration and Licensing Deals 2016-2023

$3,995.00

Ophthalmics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023

Publication date
October 2023
Number of pages
250+
Product type
Therapy profile
Available formats
PDF document
Report edition
4
SKU
CP2219

Ophthalmics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the ophthalmics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of ophthalmics deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of ophthalmics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in ophthalmics dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the ophthalmics field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in ophthalmics dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of ophthalmics deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of ophthalmics deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in ophthalmics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Key benefits

Ophthalmics Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse ophthalmics collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

 

Report scope

Ophthalmics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of ophthalmics trends and structure of deals entered into by leading biopharma companies worldwide.

Ophthalmics Collaboration and Licensing Deals includes:

  • Trends in ophthalmics dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of ophthalmics deal records covering pharmaceutical and biotechnology
  • The leading ophthalmics deals by value
  • Most active ophthalmics licensing dealmakers

In Ophthalmics Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Ophthalmics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Ophthalmics Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse ophthalmics collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in ophthalmics dealmaking

 

2.1. Introduction

2.2. Ophthalmics partnering over the years     

2.3. Ophthalmics partnering by deal type

2.4. Ophthalmics partnering by industry sector

2.5. Ophthalmics partnering by stage of development

2.6. Ophthalmics partnering by technology type

2.7. Ophthalmics partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for ophthalmics partnering

 

3.1. Introduction

3.2. Disclosed financials terms for ophthalmics partnering

3.3. Ophthalmics partnering headline values

3.4. Ophthalmics deal upfront payments

3.5. Ophthalmics deal milestone payments

3.6. Ophthalmics royalty rates

 

Chapter 4 – Leading ophthalmics deals and dealmakers

 

4.1. Introduction

4.2. Most active in ophthalmics partnering

4.3. List of most active dealmakers in ophthalmics    

4.4. Top ophthalmics deals by value

 

Chapter 5 – Ophthalmics contract document directory

                                            

5.1. Introduction

5.2. Ophthalmics partnering deals where contract document available

 

Chapter 6 – Ophthalmics dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by ophthalmics therapeutic target

 

Deal directory

 

Deal directory – Ophthalmics deals by company A-Z 2016 to 2023

Deal directory – Ophthalmics deals by technology type 2016 to 2023

 

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Ophthalmics partnering since 2016

Figure 2: Ophthalmics partnering by deal type since 2016

Figure 3: Ophthalmics partnering by industry sector since 2016

Figure 4: Ophthalmics partnering by stage of development since 2016

Figure 5: Ophthalmics partnering by technology type since 2016

Figure 6: Ophthalmics partnering by indication since 2016

Figure 7: Ophthalmics deals with a headline value

Figure 8: Ophthalmics deals with upfront payment values

Figure 9: Ophthalmics deals with milestone payment

Figure 10: Ophthalmics deals with royalty rates

Figure 11: Active ophthalmics dealmaking activity since 2016

Figure 12: Top ophthalmics deals by value since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

3SBio, 4D Molecular Therapeutics, 4P-Pharma, A*STAR Agency for Science, Technology and Research, AAVnerGene, Abbvie, AbCellera Biologics, ABL Bio, Abpro, Abzena, Accure Therapeutics, ACE Solutech, ActiveSite, ActualEyes, Acucela, Adaptive Phage Therapeutics, Adverum Biotechnologies, Aequus Pharmaceuticals, Aerie Pharmaceuticals, AffaMed Therapeutics, Affilogic, AFT Pharmaceuticals, AGC Biologics, AimMax Therapeutics, AiVita Biomedical, AJU Pharma, Aker BioMarine, Alcon Laboratories, Alexion Pharmaceuticals, Alienware, Alimera Sciences, Allergan, Alnylam Pharmaceuticals, ALS Association, Alvotech, Ambiopharm, American Academy of Ophthalmology, American Diabetes Association, Amneal Pharmaceuticals, AnGes MG, Angios, AntriaBio, Apellis Pharmaceuticals, Apexian Pharmaceuticals, Applied Genetic Technologies, Aptar Pharma, Arctic Vision, Argentum Pharmaceuticals, Ascendia Pharmaceuticals, Astellas Pharma, Attillaps Holdings, Aura Biosciences, Aurinia Pharmaceuticals, Avanzanite Bioscience, Avellino Labs, Avista Therapeutics, Axantia, AXIM Biotechnologies, AyoxxA Biosystems, BalGeunSeSang Eye Clinic, Bascom Palmer Eye Institute, Bausch & Lomb, Bausch Health Companies, Baxter International, Bayer, Beam Therapeutics, Beta Therapeutics, Betta Pharmaceuticals, Beyeonics Vision, BHVI, Bio-Techne, Bioeq IP, Biogen, BioInvent, BioLamina, BioLight, BiolineRX, Bionic Sight, Blackrock Neurotech, Bluejay Diagnostics, Blueprint Genetics, BlueRock Therapeutics, Boehringer Ingelheim, Breckenridge Pharmaceuticals, BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, BrightFocus Foundation, Brill Pharma, BVI Medical, C-Bridge Capital, California Institute for Regenerative Medicine, Cambridge Research Biochemicals, Capsida Biotherapeutics, Carl Zeiss Meditec, Case Western Reserve University, Catalyst Biosciences, CDR-Life, Celanese, Cella Therapeutics, Cell Care Therapeutics, Cell Cure Neurosciences, Cellusion, Celregen, Cerevast Therapeutics, Changchun High & New Technology Industries, Chiesi Farmaceutici, Children's Hospital Los Angeles, Children's Medical Research Institute, China Grand Pharmaceutical, China Medical System, Choroideremia Research Foundation, Clarion Medical Technologies, ClearPoint Neuro, Clearside Biomedical, Clover Therapeutics, Coave Therapeutics, Coherus Biosciences, Columbia Technology Ventures, Columbia University, Combangio, Compact Imaging, Consort Medical, Contamac, Copernicus Therapeutics, Corning, Cortigent, CROMA Pharma, CS Pharmaceuticals, Curacle, CureVac, Cyagen Biosciences, Cyclica, D. Western Therapeutics Institute, Daiichi Sankyo, DelSiTech, Dermira, Diana Davis Spencer Foundation, Digital Diagnostics, Diopsys, DNX Biopharmaceuticals, doc.ai, DotBio, Dr. Agarwal’s Eye Hospitals, Dr. Reddy's Laboratories, DSM, Duke-NUS Graduate Medical School Singapore, Duke University, Dyno Therapeutics, Eastman Chemical Company, Editas Medicine, Eleven Biotherapeutics, ElsaLys Biotech, Eluminex Biosciences, Epimune Diagnostics, Equinox Science, eSight, Eton Pharmaceuticals, Everads Therapy, Eversight, Evommune, Evotec, Exonate, EyeCRO, Eyedetec Medical, Eyegate Pharmaceuticals, EyeMedics, Eyenovia, Eyeon Therapeutics, EyePoint Pharmaceuticals, Eyevance, Eyevensys, Famy Life Sciences, Fibrogen, Find Therapeutics, Florida Pharmaceutical Products, Forge Biologics, Formosa Pharmaceuticals, Fortify Therapeutics, Fortress Biotech, Foundation Fighting Blindness, FUJIFILM Cellular Dynamics, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Galapagos, Galimedix Therapeutics, Gemini Therapeutics, Genentech, Genosity, Gentex, Gestion Univalor, Glaucoma Research Foundation, Glaukos, Glenmark Pharmaceuticals, Grifols, Gyroscope Therapeutics, Halozyme Therapeutics, HanAll Pharmaceuticals, HanchorBio, Harbour Biomed, Harrow Health, Harvard Medical School, HealPros, Healthe Care Australia, Hemera Biosciences, Hemostemix, Henlius Biotech, Hitachi Chemical, Homology Medicines, Hopstem Biotechnology, Horama, Horizon Discovery, Horizon Europe, Horizon Therapeutics, Hovione, IACTA Pharmaceuticals, IBM, Ichor Life Sciences, IDx, Ikarovec, Immervision, ImPact Biotech, Imprimis Pharmaceuticals, Indoco, Industrial Technology Research Institute, Inflammasome Therapeutics, InformedDNA, InMed Pharmaceuticals, Inserm Transfert, Intas Pharmaceuticals, Intellia Therapeutics, Intratus, Ionis Pharmaceuticals, IQVIA, IRIS, IRIS International, Iris Pharma, Israeli National Authority for Technological Innovation, iSTAR Medical, Itrom Pharmaceutical Group, Ivantis, iVeena Delivery Systems, Iveric Bio, Jackson Laboratory, Jaeb Center for Health Research Foundation, Janssen Pharmaceuticals, Janssen Research & Development, jCyte, Ji Xing Pharmaceuticals, Johns Hopkins University, Johnson & Johnson Innovation, Johnson & Johnson Vision, Joslin Diabetes Center, Kali Care, KalVista Pharmaceuticals, Kanaph Therapeutics, KC Pharmaceuticals, Kiora Pharmaceuticals, Klinge Biopharma, Kodiak Sciences, Konkuk University, Kriya Therapeutics, Kubota Vision, Kuria Therapeutics, Laboratoires Thea, Lansheng Medical, Lantheus Holding, Launch Therapeutics, Lee's Pharmaceutical, Leiden University, Leidos, LENZ Therapeutics, LGC, LianBio, Lin Bioscience, Lineage Cell Therapeutics, LLamasoft, Lochan, Lubris BioPharma, LumiThera, Lund University, Maastricht University, mAbXience, Mannin Research, Marchon Eyewear, Massachusetts Eye and Ear Infirmary, Mawson Infrastructure, Mayo Clinic, McMaster University, mCureX Therapeutics, Medical Food Solutions Research, Medical Research Foundation, Medical University of South Carolina, MedImmune, MeiraGTx, Menicon, Merck and Co, Merck Animal Health, Merz, Meyer Children's Hospital of Florence, MiniFab, Minnetronix, miRagen Therapeutics, MitoChem Therapeutics, Mitsubishi Tanabe Pharma, MolMed, Mosaic Biosciences, Mperia Therapeutics, MPI Research, Mundipharma, Mylan Pharmaceuticals, MyMD Pharmaceuticals, Nacuity Pharmaceuticals, Nanomerics, Nanoscope Therapeutics, NanoViricides, Narayana Nethralaya Foundation, NASA, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Eye Institute, National Institutes of Health, National Organization for Rare Disorders, National University of Singapore, NEMUS Bioscience, Neuraly, Neurolens, Neurophth Therapeutics, NeuroVive Pharmaceutical, Nevakar, NGM Biopharmaceuticals, Nicox, Nightstar Therapeutics, Notal Vision, Novaliq, Novartis, Noveome Biotherapeutics, Novo Nordisk, Novotech, NTC, NuEyes, Numab, Ocugen, Ocular Therapeutics, Ocular Therapeutix, Oculis, Oculogenex, Ocumension Therapeutics, OcuNexus Therapeutics, Ocuphire Pharma, Odylia Therapeutics, OKKO Health, OKYO Pharma, OliX Pharmaceuticals, Olympic Ophthalmics, Omega Therapeutics, Omeros, OmniVision Technologies, ONL Therapeutics, OphtAI, Ophthotech, Opsis Therapeutics, Opthea, Optibrand, Optifye Therapeutics, OptiKira, Optina Diagnostics, Optomed, Optometric Extension Program Foundation, Opus Genetics, Ora, Orbis, Orbit Biomedical, Oregon Health Sciences University, Oregon National Primate Research Center, Osmotica Pharmaceuticals, Osterhout Design Group, Oxford BioMedica, Oxurion, Oyster Point Pharma, PanOptica, PeptiDream, Perelman School of Medicine, PharmAbcine, Pharmaleads, Phillips-Medisize, Pieris Pharmaceuticals, Pierre Fabre, Ping An Ventures, Plex Pharmaceuticals, Polifarma, PolyPhotonix, PreCerv, Preceyes, Precise Biometrics, Precision Ocular, Precision Optics, Prevail InfoWorks, Promedica International, ProQR Therapeutics, ProtoKinetix, pSivida, PTC Therapeutics, Q BioMed, Queensland University of Technology, Quotient, Rallybio, Rayner Surgical, Ray Therapeutics, RecensMedical, Recordati, Regeneron Pharmaceuticals, Regenerx, ReGenTree, Regenxbio, Remidio Innovative Solutions, Rentschler Biotechnologie, Resilience, Retinagenix, RetinAI Medical, Retina Institute, RetroSense Therapeutics, ReVision Optics, Revision Skincare, Ribomic, RightEye, Ripple Therapeutics, Roche, Rotterdam Eye Hospital, RVL Pharmaceuticals, RxCell, Saban Research Institute of Children's Hospital Los Angeles, Sam Chun Dang Pharm, Samsara Vision, Samsung Bioepis, Samsung Biologics, SanBio, Sanofi, Santen, Santen Pharmaceutical, Santhera Pharmaceuticals, Saphetor, SATT Conectus Alsace, Schepens Eye Research Institute, Scohia Pharma, Second Sight Medical, Selagine, SemaThera, Senju Pharmaceutical, Senti Biosciences, Sentrx Animal Care, SIFI (Societa Industria Farmaceutica Italiana), Sigenics, Sight Sciences, Singapore Eye Research Institute (SERI), Singapore National Eye Centre, Sintetica, SipNose, Skye Bioscience, Slayback Pharma, Societal CDMO, Sonoma Pharmaceuticals, SparingVision, Spark Therapeutics, Staar Surgical Co, STADA Arzneimittel, Stanford University, Stanford University School of Medicine, State University of New York, Streetlab, Stuart Therapeutics, Sun Pharma Advanced Research Company, Sun Pharmaceutical, Surrozen, SwissLens, Sydnexis, SynergEyes, Taiwan Liposome Company, TALLC, Tamid Bio, Tangible Science, Taro Pharmaceuticals, Tarsius Pharma, Tarsus Pharmaceuticals, TeamedOn International, TearLab, Technological University Dublin, Teijin, Thea Open Innovation, Therakine, The Regents of the University of California, ThinkCyte, ThromboGenics, Tianjin CanSino Biotechnology, Titan Pharmaceuticals, Tobii Technology, Toolgen, Topcon, TOT BIOPHARM, Transitions Optical, Translational Research Institute for Space Health, Translatum Medicus, Trefoil Therapeutics, Trethera, TRIGR Therapeutics, Tu Dresden, Tufts Medical Center, Tufts University, twoXAR, UCB, Ulster University, Uni-Bio Science, University College London, University of British Columbia, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Cologne, University of Colorado, University of Florida, University of Florida Research Foundation, University of Hong Kong, University of Massachusetts, University of Massachusetts Medical School, University of Minnesota, University of Nebraska, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Washington, University Paris Diderot, Valeant Pharmaceuticals, ValenzaBio, Vanda Pharmaceuticals, Vasomune Therapeutics, Verana Health, Versant Health, Versea Ophthalmics, Vial, Viela Bio, ViGeneron, Vision Care Group, VisionCare Ophthalmic Technologies, Vision Essence, Vision Institute, VisionQuest Biomedical, VisionWeb, Visiox Pharma, Visus Therapeutics, Vitrisa Therapeutics, Vivani Medical, VivaVision Biotech, Vivior, Volk Optical, Vyluma, Wagner Macula Retina Center, Wakamoto Pharmaceutical, Wake Forest University, Wallace H. Coulter Foundation, Wellcome Trust, WuXi Advanced Therapies, Xbrane Bioscience, Xencor, Xequel Bio, XERIS Pharmaceuticals, XL-Protein, Yangtze River Pharmaceutical Group, YouHealth Eyetech, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical, Zhonglan Electronic Technology

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.